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Abstract
Study objective: The primary aim of this study was to investigate whether IMA levels are helpful in the
diagnosis of pulmonary embolism (PE). The secondary aim was to determine whether IMA was more
effective alone or in combination with clinical probability scores in the diagnosis of PE. Thirdly, the
sensitivity and specificity of IMA is compared with D-dimer both with and without clinical probability
scores in patients with suspected PE.
Methods:  Consecutive patients presenting to the emergency department with suspected PE were
prospectively recruited, and healthy volunteers were also enrolled as controls. D-dimer and IMA levels
were measured for the entire study group. Wells and Geneva scores were calculated and s-CTPA was
performed on all suspected PE patients.
Results: The study population consisted of 130 patients with suspected PE and 59 healthy controls. Mean
IMA levels were 0.362 ± 0.11 ABSU for Group A, the PE group (n = 75); 0.265 ± 0.07 ABSU for Group B,
the non-PE group (n = 55); and 0.175 ± 0.05 ABSU for Group C, the healthy control group (p < 0.0001).
At a cut-off point of 0.25 ABSU, IMA was 93% sensitive and 75% specific in the diagnosis of PE. PPV was
79.4% and NPV was 78.6%. Mean D-dimer levels were 12.48 ± 10.88 μg/ml for Group A; 5.36 ± 7.80 μg/
ml for Group B and 0.36 ± 0.16 μg/ml for Group C (p < 0.0001). The D-dimer cut-off point was 0.81 μg/
ml with a sensitivity of 98.9% and a specificity of 62.7%, PPV of 69.4% and NPV of 83.3%. The use of IMA
in combination with Wells and Geneva clinical probability scores was determined to have a positive impact
on these scores' sensitivity and negative predictive values.
Conclusion: IMA is a good alternative to D-dimer in PE diagnosis in terms of both cost and efficiency.
Used in combination with clinical probability scores, it has a similar positive effect on NPV and sensitivity
to that of D-dimer. The PPV of IMA is better than D-dimer, but it is still unable to confirm a diagnosis of
PE without additional investigation.
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Introduction
Background
Pulmonary embolism (PE) is a common and potentially
life-threatening disorder. Because symptoms and signs are
nonspecific, the diagnosis of PE in the emergency depart-
ment (ED) still poses difficulties [1].
Importance
None of the available laboratory tests are capable of relia-
bly excluding the diagnosis, and the clinician therefore
has to rely on such diagnostic techniques as lung scintig-
raphy, spiral computed tomographic pulmonary angiog-
raphy (s-CTPA) or pulmonary angiography [2]. New and
simple tests are therefore needed in order to exclude PE
and to reduce the number of these sophisticated imaging
techniques required.
Under acute ischemic conditions, the metal binding
capacity of albumin to transition metals such as copper,
nickel and cobalt is reduced, generating a metabolic vari-
ant of the protein generally referred to as ischemia modi-
fied albumin (IMA) [3]. IMA is a sensitive marker of
myocardial ischemia, skeletal ischemia, mesenteric
ischemia and stroke [4-7]. There is only one study in the
literature regarding the diagnostic value of IMA in the
diagnosis of PE [8].
Objectives
The primary aim of our study was to investigate whether
IMA levels are a useful marker that can be used in the diag-
nosis of PE, the secondary aim being to determine
whether IMA alone or in combination with clinical prob-
ability scores can be used as an alternative to D-dimer as a
laboratory marker in the diagnostic work-up of patients
with suspected PE.
Materials and methods
Study design
This study is a primary analysis of data collected during a
prospective, observational study at a tertiary care center.
Setting
The setting was the ED of Karadeniz Technical University,
Faculty of Medicine in the city of Trabzon in Turkey. Some
20,000 patients present to the ED annually.
Selection of participants
The protocol for the study was approved by the hospital's
local ethical committee. Patients were included in the
study if the emergency physician suspected PE. One hun-
dred forty-seven consecutive patients presenting to the ED
with suspected PE from April, 2006, to April, 2007, were
prospectively recruited for the study. Additionally, fifty-
seven healthy volunteers served as a reference for bio-
chemical parameters.
Exclusion criteria were: (i) other acute ischemic diseases
newly diagnosed during the ED visit in question, such as
acute coronary syndrome (ACS), acute ischemic cerebrov-
ascular disease, acute peripheral arterial occlusion, or
acute mesenteric ischemia; (ii) an abnormal serum albu-
min level making the determination of IMA levels impos-
sible (normal level 3,5–5,5 mg/dl); (iii) advanced liver,
kidney or heart failure; (iv) troponin-T and ECG testing
was performed for evidence of asymptomatic coronary
ischemia; (v) age <18 years; (vi) allergy to contrast mate-
rial and (vii) refusal to participate in the study. The exclu-
sion criteria applied during the enrolment of the control-
healthy group were the same as those for the patient
group. Patients were observed until discharged from the
hospital or until death.
Data collection and processing
Emergency physicians completed a questionnaire consist-
ing of details of the patient's medical history (such as risk
factors). Physical examination, chest X-ray and ECG, IMA,
D-dimer and arterial blood analysis were performed for
all patients, and both the simplified Well's and the
Geneva scores were calculated before tomographic exam-
ination [9,10].
Spiral-CTPA was performed on all patients who had no
exclusion criteria. Patients were divided into two groups
according to the s-CTPA results, Group A, the PE group,
and Group B, the non-PE group. The healthy control
group was classified as Group C. s-CTPA was not per-
formed in Group C although blood analysis for IMA and
D-dimer was carried out.
Methods of measurement
IMA measurement
Blood samples were taken from the brachial vein at time
of presentation. Reduced cobalt to albumin binding
capacity (IMA level) was analyzed using the rapid and
colorimetric method developed by Bar-Or et al. [11]. This
is based on the principle of quantitative scanning of the
free cobalts present after cobalt binding has taken place.
This means that high absorbance levels as a result of
increased amounts of free cobalt in the environment can
be determined.
D-dimer measurement
D-dimer was assayed using the quantitative, immuno-
tubidimetric STA-Liatest D-dimer kit assay from Diagnos-
tica Stago, Asnieres, France, which was run on an auto-
matic coagulation analyzer (STA-compact, Diagnostica
Stago) in a routine setting.
CT imaging and images interpretation
All patients underwent s-CTPA within 12 hours of selec-
tive pulmonary angiography using a 16 detector spiral CTRespiratory Research 2008, 9:49 http://respiratory-research.com/content/9/1/49
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scanner (Siemens Somatom Sensatio, Germany). CT scans
were reviewed by radiologists experienced in analyzing s-
CTPA. The radiologists were blinded to the results of the
D-dimer and IMA testing. The s-CTPA criteria used to
diagnose PE consisted of direct visualization of non-
occlusive endoluminal thrombus (central filling defect or
partially outlined by contrast agent) or of complete occlu-
sion by thrombus in normal-sized or enlarged vessels.
Primary data analysis
Statistical analysis was performed using the SPSS version
13.0 (SPSS, Chicago, IL, USA). For the IMA and D-dimer,
the test characteristics, sensitivity, specificity, negative and
positive predictive values were calculated according to the
s-CT results. The area beneath the receiver operating char-
acteristics (ROC) curves was used to compare the discrim-
inative power of the IMA and D-dimer tests in the
diagnosis or ruling out of PE. The compatibility of the
data with normal distribution was investigated using the
Kolmogorov-Smirnov test. Kruskal-Wallis analysis of var-
iance (Mann-Whitney U-test with post-hoc Bonferroni
correction) was used to compare IMA and D-dimer
among the groups. Statistical significance was assumed at
a level of P < 0.05.
Results
Characteristics of study subjects
A total of 147 patients with suspected PE and 59 healthy
control subjects were enrolled in the study. Seventeen
patients were excluded because of predefined criteria: ACS
(n = 7), acute ischemic cerebrovascular disorder (n = 1),
paradoxical embolism (n = 1), advanced renal insuffi-
ciency (n = 3), advanced congestive heart failure (n = 1),
peripheral arterial occlusion (n = 3), sepsis (n = 1).
All the 130 remaining suspected PE patients underwent s-
CTPA at the time of admission. Patients were divided into
two groups, Group A, the PE group (n = 75), and Group
B, the non-PE group (n = 55), according to the s-CTPA
results. The healthy control group was classified as Group
C (n = 59). Our diagnostic work-up is presented in Figure
1.
Our diagnostic work-up in suspected PE patients Figure 1
Our diagnostic work-up in suspected PE patients.
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The baseline demographic and clinical characteristics of
Groups A, B and C are given in Table 1.
Main results
The serum IMA and D-dimer levels of the groups are
shown in Table 2.
The D-dimer vs IMA levels were determined to be statisti-
cally different to one another in all groups (p < 0.0001)
The highest IMA and D-dimer levels were determined in
Group A patients, while there was also a statistically signif-
icant difference between the levels in Groups B and C (p <
0.0001). The receiver operating characteristic curve of IMA
and D-dimer for diagnosis of PE at admission is shown in
Figure 2 and 3.
The area under the curve for IMA was 0.889 (bootstrap
95% Cl, 0,842–0,936). The optimum diagnostic cut-off
point maximizing sensitivity and specificity was deter-
mined to be 0.25 ABSU, with a sensitivity of 93.1% and a
specificity of 75.5%. The corresponding PPV and NPV lev-
els were 79.4% and 78.6%, respectively. The area under
the curve for D-dimer was 0.893 (bootstrap 95% Cl,
0,845–0,941). The optimum diagnostic cut-off point
maximizing sensitivity and specificity was determined to
be 0.81 (μg/ml), with a sensitivity of 98.9% and a specifi-
city of 62.7%. The corresponding PPV and NPV levels
were 69.4% and 83.3%, respectively.
The scattergram of the serum IMA and D-dimer values in
all groups is shown in Figure 4 and 5.
Predictive values of negative IMA (<0.25 ABSU), negative
D-dimer (<0.81 μg/ml), CRP ≤ 0.59 mg/dl, Sa02 ≥ 90%,
respiratory rate ≤ 20/mi, heart rate ≤ 100/min and
PH<7.45, alone and in combination for excluding PE
diagnosed on the basis of s-CTPA, are shown in Table 3.
Group A and B Wells and Geneva clinical probability
scores were also analyzed in our study. Group C (healthy
volunteers) scores were not included in this analysis, and
statistical calculations were performed for Group A and B
patients alone.
The receiver operating characteristic curves of Wells and
Geneva scores for diagnosis of PE at admission are shown
in Figure 6 and 7. According to these,; the area under the
curve for the Wells score was 0.765 (bootstrap 95% Cl,
0.681–0.849). The optimum diagnostic cut-off point
maximizing sensitivity and specificity was found to be 2
points, with a sensitivity of 79.3% and a specificity of
48.8%. The corresponding PPV and NPV levels were
75.8% and 53.8%, respectively.
The area under the curve for the Geneva score was 0.659
(bootstrap 95% Cl, 0.558–0.759). The optimum diagnos-
tic cut-off point maximizing sensitivity and specificity was
found to be 5 points, with a sensitivity of 73.6% and a
specificity of 51.2%, respectively. The corresponding PPV
and NPV levels were 75.3% and 48.9%, respectively.
Based on the cut-off values determined, biochemical
markers and clinical probability scores were subsequently
combined. Using a positive s-CTPA as the standard for
diagnosis of PE, the diagnostic accuracy levels of the IMA,
D-dimer, Well's score, Geneva score, Well's score + IMA,
Geneva score + IMA, Well's score + D-dimer, Geneva score
+ D-dimer are shown in Table 4.
Limitations
Because our facility is a tertiary referral center and receives
many patients who have been pre-screened by outlying
hospitals and clinics, the prevalence of PE in our patients
was very high. The PPV and NPV levels for the tests and
criteria described may be different for populations with a
different prevalence of PE.
The definitive diagnosis of PE was made using s-CTPA.
The sensitivity and specificity of s-CT range from 53% to
%100 and from 81% to 100%, respectively, when pulmo-
nary arteriography is used as the standard for diagnosis of
PE [12]. For that reason, subsegmental or micro-embo-
lisms invisible under s-CTPA may be present, especially in
Group B patients. Even if this is not absolutely certain, it
may well account for some high IMA values determined in
Group B patients.
There are no data for the period following hospital dis-
charge, so there may have been patients in Group B who
developed PE subsequently.
IMA is a new biomarker, the levels of which are signifi-
cantly influenced by wide range of physiological varia-
bles, including exercise and hydration. It may also be
elevated in a number of other diseases. In our patient
selection, we eliminated patients with advanced liver, kid-
ney or congestive heart failure, which can alter IMA levels.
We were unable, however, to check for all variables which
could possibly influence IMA levels.
Discussion
The literature contains studies regarding the use of IMA in
acute ischemic conditions. It has been reported in these
that IMA can be used as a diagnostic marker, especially in
ACS [13-15]. IMA may not be specific for cardiac
ischemia. Data concerning IMA levels in non-cardiac
ischemia are limited. Some evidence suggests that IMA
increases in stroke, mesenteric ischemia, end-stage renal
disease, liver disease and some neoplasms [16].Respiratory Research 2008, 9:49 http://respiratory-research.com/content/9/1/49
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Table 1: Baseline demographic and clinical characteristics of the study population.
Group A (n = 87, 46%) Group B (n = 43, 22,8%) Group C (n = 59,31,2%)
Mean Age ± SD (years) 68.37 ± 11.55 67.30 ± 14.94 62.42 ± 10.46
Sex n % n % n %
Female 53 60.9 20 46.5 29 49.1
Male 34 39.1 23 53.5 30 50.9
Symptoms n % n %
Cough 27 31.0 14 32.6
Chest pain 42 48.3 17 39.5
Dyspnea 77 88.5 35 81.4
Hemoptysis 8 9.2 4 9.3
Syncope 18 20.7 5 11.6
Symptoms of DVT 7 8.0 1 2.3
Asymptomatic 3 3.4 1 2.3
Clinical signs Mean ± SD Mean ± SD
Heart rate 104.74 ± 23.56 103.88 ± 23.02
Respiratory rate 27.53 ± 6.26 25.65 ± 7.77
Fever 36.75 ± 0.79 36.92 ± 0.78
Systolic BP 113.39 ± 35.57 122.86 ± 28.99
Diastolic BP 72.44 ± 19.88 75.63 ± 17.85
Chest X-ray signs n % n %
Pleural effusion 28 32.2 21 48.8
Atalectasis 26 29.9 11 25.6
Diaphragm elevation 26 29,8 11 25.6
Hampton's sign 4 4.6 0
Westermach sign 1 1.1 0
Pulmonary artery dilatation 10 11.5 2 4.7
ECG signs n % n %
S1Q3T3 16 18.4 1 2.3
Sinusal tachycardia 42 48.3 18 41.9
Atrial fibrillation 14 16.1 8 18.6
T negativity 9 10.3 3 7.0
RBBB 2 2.3 0
Risk factors for VTE n % n %
Previous DVT 11 12.64 2 4.65
Previous PE 4 4.59 1 2.32
Varicose veins 8 9.19 2 4.65
Chronic venous insuffficiency 7 8.04 1 2.32
Previous stroke 12 13.79 4 9.30
COPD 18 20.68 13 30.23
CHF 27 31.03 20 46.51
Cancer 9 10.34 2 4.65
Recent surgery 22 25.28 3 6.97
Recent trauma 8 9.19 1 2.32
Immobilization 57 65.51 21 48.83
Pregnancy 2 2.29 1 2.32
Post-partum period 0 1 2.32
Obesity 10 11.49 0
Long bone fracture 5 5.74 0Respiratory Research 2008, 9:49 http://respiratory-research.com/content/9/1/49
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There is only one study in the literature about the use of
IMA for diagnostic purposes in PE. This study, by Turedi
et al., consisting of 30 patients with PE and 30 healthy
individuals, demonstrated that serum IMA levels were sig-
nificantly higher than those in healthy individuals in 97%
of patients [8]. Despite being a limited study, this research
by Turedi et al. is an indication that IMA levels might be
used in the diagnosis of PE.
Various clinical probability scores and biochemical mark-
ers are currently employed in order to exclude suspected
PE in patients without using invasive and high-cost scan-
ning tools. The most frequently used among these bio-
chemical markers is D-dimer. The negative predictive
value of D-dimer levels for ruling out a diagnosis of
thromboembolic disease has been reported as high [17].
However, D-dimer is a rather non-specific marker and its
positive predictive value is very low.
The assessment of pretest probability, allowing the catego-
rization of patients clinically suspected of having PE into
low, intermediate and high clinical probability, is an
essential step in contemporary diagnostic strategies
because such categorization helps determine the need for
and type of additional testing in patients suspected of hav-
ing pulmonary emboli [18]. The association of a low or
moderate clinical probability with a normal D-dimer
assay may confidently rule out PE without using imaging
Receiver operating characteristics of ischemia modified albumin levels Figure 2
Receiver operating characteristics of ischemia modified albumin levels.
Best-cutoff point: 0.25 ABSU 
AUC =0.889 
(Bootstrap 95% Cl, 0.842-0.936) 
Table 2: The serum IMA and D-dimer levels of the groups.
Group A Group B Group C P value
IMA levels (ABSU) ± SD 0.362 ± 0.11 0.265 ± 0.07 0.175 ± 0.05 0.0001
D-dimer levels (μg/ml) ± SD 12.48 ± 10.88 5.36 ± 7.80 0.36 ± 0.16 0.0001Respiratory Research 2008, 9:49 http://respiratory-research.com/content/9/1/49
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Table 3: Predictive value of negative IMA (<0.25 ABSU), negative D-dimer (<0.81 μg/ml), CRP ≤ 0.59 mg/dl, Sa02 ≥ 90%, respiratory 
rate ≤ 20/min, heart rate ≤ 100/min and PH<7.45, alone and in combination for excluding PE diagnosed on the basis of s-CTPA.
Observation Correct exclusion Negative predictive value
Negative IMA (<0.25 ABSU) 22/28 0.786
Negative D-dimer (<0.81 μg/ml) 5/6 0.883
Negative CRP (<0.59 mg/dl) 6/11 0.545
Sa 02 ≥ 90% 30/89 0.337
Respiratory rate ≤ 20/min 8/21 0.381
Heart rate ≤ 100/min, 22/61 0.361
PH<7.45 28/64 0.438
Negative IMA and Sa02 ≥ 90% 15/20 0.750
Negative IMA and respiratory rate ≤ 20/min 5/6 0.833
Negative IMA and heart rate ≤ 100/min, 11/14 0.786
Negative IMA and PH <7.45 22/28 0.786
Negative IMA and negative D-dimer 3/3 1.00
Negative IMA and negative CRP 3/4 0.750
Negative IMA and negative D-dimer and negative CRP 1/1 1.00
Negative IMA and Sa02 ≥ 90% and heart rate ≤ 100/min 0/0 No definition
Receiver operating characteristics of D-dimer levels Figure 3
Receiver operating characteristics of D-dimer levels.
AUC = 0.893  
(Bootstrap 95% Cl, 0.845-0.941) 
Best-cutoff point: 0.81(μg/ml)   Respiratory Research 2008, 9:49 http://respiratory-research.com/content/9/1/49
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modalities [19]. However, in the presence of a high clini-
cal probability, most clinicians believe that additional
tests are necessary [20].
Wells et al. described a first extended score, which was
rather complex and not easy to use in daily practice, and
subsequently developed a simplified one [9]. The Geneva
score has been described by Wicki et al. as a prediction
rule [10]. It has been shown in the literature that these
clinical probability scores in combination with the use of
such biochemical markers as CRP and D-dimer can be
useful in excluding PE [21-23]. However, the sensitivity
and specificity problems associated with both probability
scores and markers such as D-dimer make the identifica-
tion of new, more accurate markers desirable.
In this study we investigated the diagnostic value of IMA
in PE and whether or not IMA levels enhanced the diag-
nostic accuracy of commonly used risk stratification
scales.
With a cut-off value of 0.25 ABSU, IMA sensitivity in the
diagnosis of PE was 93.1%, specificity was 75.5%, positive
predictive value was 79.4% and negative predictive value
was 78.6%. The PPV of a positive IMA is better than the
PPV of a positive D-dimer in the diagnosis of PE. D-dimer
sensitivity and NPV have been demonstrated to be better
than that of IMA and NPV. However, the results for IMA
are very close to those for D-dimer and suggest that it can
be used as an alternative marker. Used together with clin-
ical probability scores it has a similarly positive effect on
NPV and sensitivity to that of D-dimer. In addition IMA is
a rapid and low-cost technique. Compared with D-dimer,
the costs involved are some 100–200 times lower. In
order to reduce patient exposure to radiation and lengthy
and high-cost radiological tests, there is a need for eco-
nomical and high-accuracy markers. Although it cannot
be said, on the basis of the results of our study, that IMA
is superior to D-dimer for that purpose, it may still be
regarded as an alternative to D-dimer in terms of cost and
the results determined. More comprehensive studies now
need to be carried out on this subject.
In conclusion, IMA is a good alternative to D-dimer in the
exclusion of PE diagnosis in terms of cost and efficiency.
When used in combination with clinical probability
scores, it has a similar positive effect on sensitivity to that
of D-dimer and a superior one to that of NPV.
Scattergram of the serum IMA levels in all groups Figure 4
Scattergram of the serum IMA levels in all groups.
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The PPV of IMA is better than D-dimer but is still unable
to rule out a diagnosis of PE without additional studies.
Wider-ranging studies in the future may mean that IMA
becomes an important marker in the diagnostic approach
to PE.
Abbreviations
IMA: ischemia-modified albumin; PE: pulmonary embo-
lism; ED: emergency department; s-CTPA: spiral com-
puted tomographic pulmonary angiography; ABSU:
absorbance units; PPV: positive predictive value; NPV:
Scattergram of the serum D-dimer levels in all groups Figure 5
Scattergram of the serum D-dimer levels in all groups.
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negative predictive value; ACS: acute coronary syndrome;
ECG: electrocardiography; DTT: dithiotheitol; SPSS: statis-
tical package for the social sciences; ROC: receiver operat-
ing characteristics; DVT: deep vein thrombosis; SD:
standard deviation; BP: blood pressure; RBBB: right bun-
dle brunch block; VTE: venous thromboembolism;
COPD: chronic obstructive pulmonary disease; CHF: con-
gestive heart failure; AUC: area under the curve; CRP: C-
reactive protein; Sa02: oxygen saturation.
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